Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Receivables: 2022-2025

Historic Change in Receivables for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Sep 2025 value amounting to -$54,000.

  • Corvus Pharmaceuticals' Change in Receivables fell 254.29% to -$54,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$38,000, marking a year-over-year increase of 89.67%. This contributed to the annual value of $49,000 for FY2024, which is 108.72% up from last year.
  • According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Change in Receivables is -$54,000, which was down 871.43% from $7,000 recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Change in Receivables ranged from a high of $130,000 in Q3 2022 and a low of -$429,000 during Q2 2023.
  • In the last 3 years, Corvus Pharmaceuticals' Change in Receivables had a median value of $5,000 in 2024 and averaged -$62,778.
  • In the last 5 years, Corvus Pharmaceuticals' Change in Receivables soared by 218.18% in 2024 and then crashed by 254.29% in 2025.
  • Over the past 4 years, Corvus Pharmaceuticals' Change in Receivables (Quarterly) stood at $85,000 in 2022, then crashed by 82.35% to $15,000 in 2023, then crashed by 66.67% to $5,000 in 2024, then tumbled by 254.29% to -$54,000 in 2025.
  • Its Change in Receivables was -$54,000 in Q3 2025, compared to $7,000 in Q2 2025 and $4,000 in Q1 2025.